Selnoflast (development codes RO7486967, RG-6418, IZD334) is an experimental small-molecule drug developed by Hoffmann-La Roche for the treatment of neuroinflammatory conditions. It is an orally active, selective, and reversible inhibitor of the NLRP3 inflammasome, a key component of the innate immune system involved in inflammatory responses.
Selnoflast (development codes RO7486967, RG-6418, IZD334) is an experimental small-molecule drug developed by Hoffmann-La Roche for the treatment of neuroinflammatory conditions. It is an orally active, selective, and reversible inhibitor of the NLRP3 inflammasome, a key component of the innate immune system involved in inflammatory responses.
Source: Wikipedia "Selnoflast" · CC BY-SA 4.0
Share this article: X · Bluesky